AstraZeneca Investors Get Vaccine Testing Suit Lead Plaintiff

April 29, 2021, 4:56 PM

AstraZeneca PLC investors secured a lead plaintiff in federal court in New York for their would-be class suit accusing the company of misleading them about its coronavirus vaccine testing process.

The parties vying for the lead plaintiff role stipulated that a retirement plan and an individual investor, working together, could best represent their interests in the suit. Judge J. Paul Oetken of the U.S. District Court for the Southern District of New York approved their pick.

AstraZeneca allegedly failed to tell the investors about problems with its clinical trials that could hamper its ability to put out a successful vaccine...

To read the full article log in.

Learn more about a Bloomberg Law subscription.